Clinical trials: Affective Disorder
Bipolar Depression
Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression
The study will evaluate the efficacy and safety of ITI-007 (Lumateperone) in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode. The study will be conducted in two parts, Part A and Part B.
- Trial name
- NCT02600494
- Testing
- ITI-007 (Lumateperone)
- Where
- 55 sites in United States
- Volunteers
- 554 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Major Depressive Disorder, Depression
Individual Patient Esmethadone (REL-1017) Expanded Access Program
To provide expanded access of esmethadone (REL-1017) to patients with a serious or immediately life-threatening disease or condition that may potentially benefit from esmethadone (REL-1017) who do not have access to other…
- Trial name
- NCT06009003
- Testing
- REL-1017
- Sponsor
- Relmada Therapeutics, Inc.
Mood Disorders
An Open-Label Trial Measuring Satisfaction And Convenience Of Two Formulations Of Lamotrigine In Subjects With A Mood Disorder
To determine the convenience and satisfaction of new orally disintegrating tablet formulation (ODT) of lamictal in subjects with a mood disorder.
- Trial name
- NCT00579982
- Testing
- Lamotrigine
- Where
- 18 sites in United States
- Volunteers
- 97 people
- Sponsor
- GlaxoSmithKline
Depression - Major Depressive Disorder, Transcranial Alternating Current Stimulation
Individualized Non-invasive Brain Stimulation for the Treatment of Major Depressive Disorder
The purpose of this research study is to study a closed-loop transcranial alternating current stimulation (tACS) device to evaluate feasibility of the product in a clinical trial and collect preliminary data on potential effects…
- Trial name
- CL-tACS RCT (NCT06874374)
- Testing
- Closed-loop tACS
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Pulvinar Neuro, LLC
Bipolar Disorder
A Study of the Relationship of Psychosocial Function With Mood Symptoms in Offspring of Parents With Bipolar Disorder
The primary purpose of this study is to compare, over 24 months, the time spent with clinically significant mood symptoms (ie, mania, depression), as measured by the Longitudinal Interval Follow-Up Evaluation (LIFE) and the…
- Trial name
- NCT03017781
- Where
- 20 sites in United States
- Volunteers
- 224 people
- Sponsor
- Janssen Research & Development, LLC
Bipolar Disorder
A Six-week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.
This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed.
- Trial name
- NCT00282464
- Testing
- Geodon (Ziprasidone)
- Where
- 43 sites in United States
- Volunteers
- 392 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
A Pharmacokinetic Study of the Relative Bioavailability of Paliperidone ER Formulations With Different Release Profiles and a Comparison to Paliperidone IR
The primary purpose of this study is to evaluate the pharmacokinetics and relative bioavailability of paliperidone ER formulations with slow, target, and fast in vitro release rates after administration of a single 12 mg dose.
- Trial name
- NCT00791193
- Testing
- Paliperidone ER
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Depressive Disorder, Treatment-Resistant
A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression
The purpose of this study is to evaluate how well esketamine nasal spray works in improving depressive symptoms in participants with treatment resistant depression (TRD).
- Trial name
- NCT07053345
- Testing
- Esketamine 56 mg, Esketamine 84 mg
- Where
- 6 sites in South Korea
- Volunteers
- 47 people
- Sponsor
- Janssen Korea, Ltd., Korea
Bipolar Disorder, Schizophrenia
Event Marker Ingested To Trigger Event Recorder 3.0 Psychiatry Study
Feasibility study of using a digital health feedback system (DHFS) to monitor medication-taking and physiologic and behavioral parameters in patients with bipolar disorder or schizophrenia.
- Trial name
- EMITTER3PSY (NCT01804257)
- Testing
- Digital Health Feedback System
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Proteus Digital Health, Inc.
Major Depression, Dysthymia
Implementation of Harmonized Depression Outcome Measures in a Health System
Working with a health system, the investigators will recruit practices to participate in the pilot study, consent and enroll patients with major depressive disorder, and collect the PHQ-9 from those patients at three timepoints…
- Trial name
- NCT04235712
- Testing
- Harmonized Depression Outcome Measures
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- OM1, Inc.
Major Depressive Disorder
A Relative Bioavailability Food Effect Study of LY03005
The objective if this study is to assess the relative bio-availability of single oral doses of 80 mg LY03005 tablets administered to healthy subjects under fed versus fasted conditions in a 2-period, crossover trial.
- Trial name
- NCT03822065
- Testing
- LY03005
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Major Depressive Disorder
Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder
The purpose of this study is to assess the safety and efficacy of Lu AA21004 in participants with major depressive disorder after completion of an 8-week double-blind treatment period in a preceding study (Lu AA21004/CCT-003…
- Trial name
- NCT01395147
- Testing
- Lu AA21004
- Where
- 32 sites in Japan
- Volunteers
- 119 people
- Sponsor
- Takeda
Depressive Disorder, Major
Study to Evaluate the Performance Validity and Test-Retest Reliability of a Computer-Administered Cognitive Test Battery in Participants With Major Depressive Disorder (MDD)
The purpose of this study is to examine concurrent validity of 8 computerized tests intended for the assessment of cognitive function in participants with Major Depressive Disorder (MDD), relative to 8 corresponding and…
- Trial name
- NCT03014544
- Testing
- Computer- administered test battery, Examiner- administered test battery
- Where
- 20 sites in United States
- Volunteers
- 585 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder
To evaluate the efficacy and the safety of ASC-01 (aripiprazole/sertraline combination) compared to sertraline monotherapy in patients with major depressive disorders who have responded incompletely to sertraline monotherapy.
- Trial name
- NCT02046564
- Testing
- ASC-01
- Where
- 29 sites in Australia, Japan and 3 more
- Volunteers
- 412 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder
Safety and Tolerability of Zelquistinel in Normal Human Volunteers
To evaluate the safety and tolerability of single ascending doses of zelquistinel in normal human volunteers
- Trial name
- NCT04981561
- Testing
- zelquistinel
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Syndeio Biosciences, Inc
Depressive Disorder
An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder
The objective is to evaluate the efficacy and safety of two doses of SSR149415 (250 mg and 100 mg twice daily) compared to placebo and escitalopram 10 mg once daily in outpatients with major depressive disorder.
- Trial name
- NCT00358631
- Testing
- SSR149415
- Where
- United States
- Volunteers
- 319 people
- Sponsor
- Sanofi
Bipolar Disorder
Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)
The purpose of this study is to assess the safety and tolerability of ziprasidone during a long-term open label study in children and adolescents (ages 10-17) with Bipolar I Disorder (Manic or Mixed).
- Trial name
- NCT01124877
- Testing
- ziprasidone oral capsules
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Major Depressive Disorder
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
This is a Double-blind study wherein patients with Major Depressive Disorder (MDD) will receive either from 1 to 3 mg a day of study medication (OPC-34712)or placebo (an inactive substance) in addition to an FDA approved…
- Trial name
- STEP-D222 (NCT01052077)
- Testing
- OPC-34712, ADT
- Where
- 43 sites in United States
- Volunteers
- 773 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder
A Pharmacokinetic Study of Lithium Before and During Topiramate Dosing in Bipolar Disorder Patients
The purpose of this study is to determine the initial (after 1-week of maintenance dosing) and extended (after 3-weeks of maintenance dosing) effect of topiramate, at doses up to 600 mg/day, on the steady-state pharmacokinetics…
- Trial name
- NCT00986128
- Testing
- topiramate
- Volunteers
- 32 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Major Depressive Disorder
A Study of Intermittent Doses of CERC-301 in MDD
There is a significant unmet medical need for rapidly acting treatment of subjects with severe major depressive disorder (MDD) who have not adequately responded to antidepressant therapy.
- Trial name
- NCT02459236
- Testing
- CERC-301
- Where
- 13 sites in United States
- Volunteers
- 115 people
- Sponsor
- Avalo Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.